Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Clinical trial NCT04231864 · WITHDRAWN

Trial details

NCT number: NCT04231864
Sponsor: Alain Algazi
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Epstein-Barr Virus Positive Metastatic Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma Stage III Nasopharyngeal Carcinoma Stage IV Nasopharyngeal Carcinoma Stage IVA Nasopharyngeal Carcinoma Stage IVB Nasopharyngeal Carcinoma

Start date: 2020-12-01
Primary completion: 2022-04-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.